TNFRSF1B and neoplasm: By targeting cancer cells, T-regs, MDSCs, and B-regs, as well as other immunosuppressive cells using TNFR2-specific CAR T cells, the negative impact of these cells in the BC TME can be significantly diminished and an efficient anti-tumor immune response can be reestablished.